Collegium Pharmaceutical Inc(COLL) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting. The company also offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. In addition, it offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Current Price

$22.20

RSI

36.892

Beta:

1.038058

February 25, 2021
47.5K
301M

-7.376 %
-2.808 %
429.941 %
507.957 %

$281,134,000
$295,792,000
$260,283,000
$28,476,000
$1,617,000
$0
-5.214 %
13.642 %
814.043 %
1661.039 %
0.000 %

$27,582,000
$-19,717,000
$-49,051,000
$-68,669,000
$-59,677,000
$-27,255,000
171.485 %
148.775 %
39.995 %
-13.095 %
-54.329 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.